top of page

No-Exam Term Life Insurance With Cirrhosis or Liver Disease: Why Most Programs Require Full Review

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

"Liver disease" is a broad label. Underwriting usually wants to know the cause (for example viral, fatty liver, alcohol-related) and the severity history, which is why instant programs often won't finalize quickly.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

Liver Disease: Cause + Severity Are Everything

Underlying cause and whether it's controlled or resolved

Severity indicators (complications, hospitalizations, symptoms)

Medication history and ongoing monitoring

Liver disease exists on a spectrum from mild fatty changes with no significant fibrosis to end-stage decompensated cirrhosis with life-threatening complications, and underwriters assess it across that entire range rather than treating any liver diagnosis as a monolithic category. The Child-Pugh scoring system - which classifies liver disease as Class A (mild, compensated), Class B (moderate), or Class C (severe, decompensated) - provides the clinical framework that shapes underwriting decisions, either explicitly when a carrier requests the score or implicitly through the specific questions they ask about symptoms, laboratory values, and hospitalization history. A Child-Pugh Class A patient with well-compensated cirrhosis, normal or near-normal albumin, controlled bilirubin, no ascites, and no hepatic encephalopathy occupies a fundamentally different risk position than a Child-Pugh Class C patient with severe decompensation. Most carriers that will consider compensated cirrhosis at all require the applicant to be firmly in Class A, with recent laboratory values supporting that classification - Class B and C cases are typically declined or placed into extended postponement pending stabilization.

Certain clinical complications of advanced liver disease, collectively referred to as decompensation events, function as hard stop signals in the underwriting process. Esophageal or gastric variceal bleeding - caused by portal hypertension diverting blood through fragile vessels - is a life-threatening event with high recurrence risk and is treated as a major red flag. Ascites, the accumulation of fluid in the abdominal cavity due to portal hypertension and reduced albumin synthesis, indicates that the liver can no longer perform its synthetic and regulatory functions adequately. Spontaneous bacterial peritonitis (SBP) is an infection of ascitic fluid that signals immune compromise related to liver failure. Hepatic encephalopathy - confusion, altered consciousness, or personality changes resulting from the liver's inability to clear ammonia and other toxins - is a direct indicator of hepatic decompensation. Any of these events in the medical record triggers significantly more restrictive underwriting, and most carriers will decline or apply very long postponement periods when decompensation has occurred.

The underlying etiology of cirrhosis provides underwriters with crucial context about disease trajectory and the likelihood of future stability or progression. Alcoholic cirrhosis requires rigorously documented sobriety, with most carriers wanting to see at least two to five years of continuous abstinence confirmed by clinical records, physician attestations, and the absence of alcohol-related complications during that period. NASH (non-alcoholic steatohepatitis) and NAFLD-related cirrhosis are increasingly common and often more insurable in earlier fibrotic stages when metabolic risk factors - obesity, insulin resistance, dyslipidemia - are being actively managed through lifestyle and pharmacological intervention. Hepatitis C patients who achieved sustained virologic response (SVR) - meaning the virus was eliminated and viral load has been undetectable for at least 12 weeks post-treatment - represent a particularly favorable category, because the causal agent driving hepatic inflammation and fibrosis has been permanently removed, halting further viral-driven liver damage.

Liver fibrosis staging from biopsy or non-invasive fibroscan assessment provides underwriters with far more actionable data than a clinical diagnosis label alone. The Metavir scale - running from F0 (no fibrosis) through F1 (portal fibrosis), F2 (periportal fibrosis), F3 (bridging fibrosis), and F4 (cirrhosis) - allows underwriters to assess the actual structural severity of liver damage rather than inferring it from symptoms. An applicant with Metavir F1 or F2 fibrosis who has addressed the underlying cause of their liver disease - through SVR for hepatitis C, sustained sobriety for alcoholic liver disease, or consistent metabolic management for NASH - presents a very different actuarial risk than one with confirmed F4 cirrhosis and ongoing exposure to the causative factor. Providing fibrosis staging documentation upfront, rather than waiting for the carrier to initiate a request through the attending physician statement process, can meaningfully shorten the overall underwriting timeline.

If your liver disease has not been formally staged through a liver biopsy or fibroscan, underwriting teams may request that documentation before they are willing to make a coverage decision. This is not an unusual request - it reflects the carrier's need to assess actual structural disease severity rather than relying on clinical impressions or symptom descriptions alone, which can vary significantly across providers. Gathering staging documentation in advance of submitting an application prevents unnecessary delays during the review process and demonstrates to the underwriter that the applicant is approaching the process transparently and collaboratively. If a formal fibrosis assessment hasn't been done recently and your hepatologist believes it is clinically warranted for ongoing management purposes, completing it serves both your long-term health monitoring and your insurance application simultaneously - a dual benefit that makes the step worth pursuing proactively.

For the broader term life overview and how no-exam underwriting works (and when full review is required), see: https://www.careproinsurance.com/instant-term-life-insurance

This is educational content that does not constitute professional legal, medical, or tax guidance. Quoting gives you a general price range, but underwriting sets the actual numbers.

Frequently Asked Questions

Can I get no-exam term life insurance with cirrhosis?

Sometimes, but many accelerated/no-exam programs are restrictive. Options depend on cause, severity, stability, and carrier guidelines. Underwriting applies.

Why do instant programs screen out liver disease?

Because liver disease severity varies, and carriers typically need more context (cause, complications, monitoring) than an automated track can evaluate.

Does fatty liver count as cirrhosis for underwriting?

Not always. Fatty liver and cirrhosis are different, but underwriting depends on what has been diagnosed and how severe it is. Carriers may request more detail.

Will I need a medical exam for liver disease history?

Not always, but additional documentation is common. Requirements depend on coverage amount, your history, and the carrier's underwriting approach.

How can I keep quotes realistic with liver disease history?

Use accurate details about diagnosis timing, stability, and any complications. Quotes can change if underwriting assumptions don't match your medical history.

I had hepatitis C and achieved SVR - does a past cirrhosis diagnosis still affect my life insurance options?

Achieving SVR is one of the most favorable developments in the underwriting of hepatitis C-related liver disease. Carriers recognize that SVR eliminates the primary driver of ongoing liver damage, substantially reducing future progression risk. Whether a past cirrhosis diagnosis still affects your options depends on the degree of fibrosis present when SVR was achieved, whether liver function has improved since treatment, and whether any decompensation events occurred. Applicants with early-stage fibrosis who achieved SVR and now have stable, normal liver function tests are in a strong position; those with F4 cirrhosis and prior decompensation face more restrictive underwriting even after viral cure.

What is the Child-Pugh score and how does it affect my life insurance underwriting?

The Child-Pugh score is a clinical classification tool that assesses liver disease severity using five parameters: total bilirubin, serum albumin, INR (a clotting measure), degree of ascites, and grade of hepatic encephalopathy. Class A indicates compensated cirrhosis with relatively preserved liver function. Classes B and C indicate progressive decompensation. In underwriting, Class A is the only category where standard coverage is realistically possible - and even then, it requires confirmed compensated status with supporting labs. Class B and C cases typically result in postponement or decline until a documented period of stability and compensation has been established.

How do underwriters treat NAFLD or fatty liver disease differently from cirrhosis?

Simple NAFLD - fatty changes in the liver without significant inflammation or fibrosis - is generally treated as a minor or even non-rated finding by most underwriters, particularly when the applicant is actively managing the contributing metabolic factors. NASH, which involves inflammation and progressive fibrosis, requires more attention. The critical distinction is always the degree of fibrosis: F0 through F2 is evaluated very differently from F4 cirrhosis, even when both result from the same underlying NAFLD pathway. Formal fibrosis staging via biopsy or fibroscan is what allows underwriters to draw that distinction precisely - without staging data, the underwriting review will proceed more slowly and conservatively.

Get Covered With The Right Plan

Liver disease underwriting is driven by cause and severity. This page explains what carriers usually look for and why instant tracks often don't fit.

Compare term life options

bottom of page